Trius Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative antibiotics for life-threatening infections. The company's lead investigational drug is tedizolid phosphate (TR-701), a once daily, IV and orally-administered second generation oxazolidinone in Phase 3 clinical development for the treatment of serious infections, including MRSA.
The company announced today that it has reached its enrollment objective of 658 patients in the last of its two Phase 3 clinical trials of tedizolid phosphate for the treatment of acute bacterial skin and skin structure infections. The key Phase 3 trial examines the efficacy and safety of a six-day course of tedizolid administered once a day versus a 10-day course of linezolid (Zyvox) administered twice a day to patients.
Last year, Trius completed its earlier study testing the oral drug dosing of tedizolid under the same trial design and endpoints as the current Phase 3 trial. The trial achieved all primary and secondary efficacy outcomes and showed significant safety and tolerability improvements versus linezolid.
The company remains on schedule to report top-line results from the Phase 3 study in early 2013. For additional information about Trius Therapeutics and its tedizolid phosphate treatment for skin infections, please visit www.triusrx.com.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html